Larimar Therapeutics Inc

Larimar Therapeutics, Inc. (Nasdaq: LRMR) is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Its lead compound, nomlabofusp (CTI-1601), is a first-in-class mitochondrial protein replacement therapy designed to directly address systemic frataxin (FXN) deficiency in patients with Friedreich's ataxia (FA), a rare progressive neurodegenerative disease affecting approximately 20,000 patients globally (roughly 5,000 in the U.S.). FA is caused by a genetic defect that reduces frataxin levels, leading to loss of coordination, slurred speech, scoliosis, diabetes, cardiovascular disease, and early mortality (life expectancy of 30-50 years). Nomlabofusp uses a cell-penetrating peptide to deliver mature human frataxin directly to mitochondria, targeting the root molecular cause of the disease. The company has completed four clinical studies (Phase 1 SAD and MAD, Phase 2 dose-exploration, and adolescent PK) and is conducting a long-term open label study while pursuing a rolling BLA submission for accelerated approval with the FDA. Nomlabofusp has received multiple regulatory designations including Breakthrough Therapy, START Pilot Program, Rare Pediatric Disease, Orphan Drug (US and EU), Fast Track, PRIME (EU), and ILAP (UK). Larimar also plans to leverage its intracellular delivery platform to design fusion proteins targeting additional rare diseases characterized by deficiencies in intracellular bioactive compounds. The company holds composition of matter patents extending to 2040 with additional IP protection through 2045. Updated Aug 4, 2026